Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting

European Journal of Clinical Pharmacology

Volumn 67, Issue 12, 2011, Pages 1223-1229

  Gökalp, Osman ^a   Gunes, Arzu ^b,e   Çam, Hakan ^c   Cure, Erkan ^c   AydIn, Osman ^c   Tamer, Mehmet Numan ^c   Scordo, Maria Gabriella ^b   Dahl, Marja Liisa ^b,d  

^a DICLE UNIVERSITY   (Turkey)

^b UPPSALA UNIVERSITY   (Sweden)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

CYP2C19; CYP2C8; CYP2C9; Gliclazide; Glimepiride; Glipizide; Hypoglycaemic attacks; Polymorphism; Sulphonylurea

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 2C8 GENE; CYTOCHROME P450 2C9 GENE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HEADACHE; HEART PALPITATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOGLYCEMIA; MALE; METABOLIC CAPACITY; MOLECULAR PATHOLOGY; NAIL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PRURITUS; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; SWEATING; TREMOR; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SULFONYLUREA COMPOUNDS;

EID: 82455167877     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1078-4     Document Type: Article

References (27)

1. K Asplund BE Wiholm F Lithner 1983 Glibenclamide-associated hypoglycaemia: a report on 57 cases Diabetologia 24 6 412 417 6411511 10.1007/BF00257338 1:STN:280:DyaL3s3ovVWisQ%3D%3D
2. A Holstein EH Egberts 2003 Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes Exp Clin Endocrinol Diabetes 111 7 405 414 14614647 10.1055/s-2003-44287 1:CAS:528:DC%2BD3sXpsFalt7o%3D (Pubitemid 37486432)
3. J Kirchheiner I Roots M Goldammer B Rosenkranz, et al. 2005 Effect of genetic polymorphisms in cytochrome P450 (CYP) 2 C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance Clin Pharmacokinet 44 12 1209 1225 16372821 10.2165/00003088-200544120-00002 1:CAS:528:DC%2BD28XitFOls74%3D (Pubitemid 41832564)
4. DJ Elliot LBC Suharjono EM Gillam, et al. 2007 Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination Br J Clin Pharmacol 64 4 450 457 17517049 10.1111/j.1365-2125.2007. 02943.x 1:CAS:528:DC%2BD2sXht1Srt73E (Pubitemid 47404317)
5. B Tan YF Zhang XY Chen XH Zhao, et al. 2009 The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects Eur J Clin Pharmacol 66 2 145 151 19847408 10.1007/s00228-009-0736-2
6. CR Lee JA Goldstein JA Pieper 2002 Cytochrome P450 2 C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 3 251 263 11927841 10.1097/00008571-200204000-00010 1:CAS:528:DC%2BD38XnsFKqsLc%3D (Pubitemid 34596790)
7. U Yasar E Eliasson ML Dahl I Johansson, et al. 1999 Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 254 3 628 631 9920790 10.1006/bbrc.1998.9992 1:CAS:528:DyaK1MXhtVegtrs%3D (Pubitemid 29290517)
8. G Ragia I Petridis A Tavridou D Christakidis, et al. 2009 Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas Pharmacogenomics 10 11 1781 1787 19891554 10.2217/pgs.09.96 1:CAS:528:DC%2BD1MXhtlOiu77N
9. A Holstein A Plaschke M Ptak EH Egberts, et al. 2005 Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents Br J Clin Pharmacol 60 1 103 106 15963101 10.1111/j.1365-2125.2005.02379.x 1:CAS:528:DC%2BD2MXmvF2ktrY%3D (Pubitemid 40942788)
10. A Holstein C Hammer M Hahn NS Kulamadayil, et al. 2011 Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients Expert Opin Drug Saf 9 5 675 681 10.1517/14740338.2010.492777
11. ML Becker LE Visser PH Trienekens A Hofman, et al. 2008 Cytochrome P450 2 C9*2 and*3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus Clin Pharmacol Ther 83 2 288 292 17597710 10.1038/sj.clpt.6100273 1:STN:280:DC%2BD1c7gtFOqtQ%3D%3D
12. Z Desta X Zhao JG Shin DA Flockhart 2002 Clinical significance of the cytochrome P450 2 C19 genetic polymorphism Clin Pharmacokinet 41 12 913 958 12222994 10.2165/00003088-200241120-00002 1:CAS:528:DC%2BD38XotlGisbg%3D (Pubitemid 35168437)
13. SC Sim C Risinger ML Dahl E Aklillu, et al. 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 1 103 113 16413245 10.1016/j.clpt.2005.10.002 1:CAS:528:DC%2BD28XksVGltw%3D%3D (Pubitemid 43069582)
14. G Ragia KI Arvanitidis A Tavridou VG Manolopoulos 2009 Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece Pharmacogenomics 10 1 43 49 19102714 10.2217/14622416.10.1.43 1:CAS:528:DC%2BD1cXhsFCisLbM
15. H Shao XM Ren NF Liu GM Chen, et al. 2010 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers J Clin Pharm Ther 35 3 351 360 20831536 10.1111/j.1365-2710.2009.01134.x 1:CAS:528:DC%2BC3cXns1Cht70%3D
16. Y Zhang D Si X Chen N Lin, et al. 2007 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects Br J Clin Pharmacol 64 1 67 74 17298483 10.1111/j.1365-2125.2007.02846.x 1:CAS:528:DC%2BD2sXosFSns7g%3D (Pubitemid 46934414)
17. D Dai DC Zeldin JA Blaisdell B Chanas, et al. 2001 Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 7 597 607 11668219 10.1097/00008571-200110000-00006 1:CAS:528:DC%2BD3MXotFWlt7c%3D (Pubitemid 32953585)
18. CL Aquilante LR Bushman SD Knutsen LE Burt, et al. 2008 Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers Hum Genomics 3 1 7 16 19129086 1:CAS:528:DC%2BD1cXhsVyms7vM
19. M Niemi JB Leathart M Neuvonen JT Backman, et al. 2003 Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide Clin Pharmacol Ther 74 4 380 387 14534525 10.1016/S0009-9236(03)00228-5 1:CAS:528:DC%2BD3sXnvVyks78%3D (Pubitemid 37222859)
20. A Tornio M Niemi PJ Neuvonen JT Backman 2008 Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone Drug Metab Dispos 36 1 73 80 17913794 10.1124/dmd.107.018010 1:CAS:528:DC%2BD1cXmtFGksw%3D%3D
21. N Bahadur JB Leathart E Mutch D Steimel-Crespi, et al. 2002 CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 11 1579 1589 12429347 10.1016/S0006-2952(02)01354-0 1:CAS:528:DC%2BD38XosFKls7o%3D (Pubitemid 35333419)
22. U Yasar S Lundgren E Eliasson A Bennet, et al. 2002 Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms Biochem Biophys Res Commun 299 1 25 28 12435384 10.1016/S0006-291X(02)02592-5 1:CAS:528:DC%2BD38XosVertL0%3D (Pubitemid 35366030)
23. H Xu KM Williams WS Liauw M Murray, et al. 2008 Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide Br J Pharmacol 153 7 1579 1586 18204476 10.1038/sj.bjp.0707685 1:CAS:528:DC%2BD1cXktVWms74%3D (Pubitemid 351481511)
24. R Wang K Chen SY Wen J Li, et al. 2005 Pharmacokinetics of glimepiride and cytochrome P450 2 C9 genetic polymorphisms Clin Pharmacol Ther 78 1 90 92 16003298 10.1016/j.clpt.2005.03.008 1:CAS:528:DC%2BD2MXlvFKqsrw%3D (Pubitemid 40956936)
25. M Niemi I Cascorbi R Timm HK Kroemer, et al. 2002 Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes Clin Pharmacol Ther 72 3 326 332 12235454 10.1067/mcp.2002.127495 1:CAS:528:DC%2BD38XotVSmurY%3D
26. RS Kidd AB Straughn MC Meyer J Blaisdell, et al. 1999 Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele Pharmacogenetics 9 1 71 80 10208645 10.1097/00008571-199902000-00010 1:CAS:528:DyaK1MXjtlyqsLg%3D (Pubitemid 29176726)
27. D Tomalik-Scharte U Fuhr M Hellmich D Frank, et al. 2011 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide Drug Metab Dispos 39 5 927 932 21270106 10.1124/dmd.110.036921 1:CAS:528: DC%2BC3MXls1Ojurk%3D